SCHEMBL2833900

SCHEMBL2833900

C=C(C(=O)OCc1ccccc1)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KMT2A Q03164 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
MEN1 O00255 1/20 0.48
CES1 P23141 1/20 0.46
PTPRC P08575 1/20 0.46
PTPN1 P18031 1/20 0.46
LMNA P02545 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HCAR2 Q8TDS4 1/20 0.45
HTT P42858 1/20 0.43
P2RX4 Q99571 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10791920 0.88 KMT2A (0.50) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL1592263 0.84 ALDH1A1 (0.52) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL16672682 0.83 HCAR2 (0.47) ALDH1A1TDP1MAPK1L3MBTL1CES1
SCHEMBL19185364 0.83 ALDH1A1 (0.55) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL18287624 0.83 ALDH1A1 (0.55) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL14101169 0.82 ALDH1A1 (0.53) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL28107631 0.82 CA1 (0.47) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL1320975 0.80 ALDH1A1 (0.55) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL4918220 0.80 ALDH1A1 (0.47) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL2678884 0.80 ALDH1A1 (0.59) ALDH1A1KMT2ATDP1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-62241906-A None JP disclosed
US-12324802-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-10 US disclosed
US-20250122218-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-04-17 US disclosed
EP-4476230-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2024-12-18 EP disclosed
EP-4247817-A1 MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-09-27 EP disclosed
CN-116670140-A Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-08-29 CN disclosed
WO-2023154291-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed
WO-2023154291-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed
CN-116171154-A Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-05-26 CN disclosed
US-20230099745-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) 2023-03-30 US disclosed
US-6586530-B1 controlled radical (co)polymerization process to produce the low surface tension (meth)acrylate containing block copolymers. PPG INDUSTRIES OHIO, INC. 2003-07-01 US disclosed
US-6583223-B2 First block is radically polymerizable fluoroalkyl(meth)acrylate monomer, second block is ethylenically unsaturated monomer that is free of hydroxyl groups and amine groups; thermosetting reactants PPG INDUSTRIES OHIO, INC. 2003-06-24 US disclosed
US-20030114593-A1 Low surface tension (meth) acrylate containing block copolymer prepared by controlled radical polymerization PPG INDUSTRIES OHIO, INC. 2003-06-19 US disclosed
US-20030100675-A1 Coating compositions which contain a low surface tension (meth) acrylate containing block copolymer flow control agent PPG INDUSTRIES OHIO, INC. 2003-05-29 US disclosed
US-20030096929-A1 Copolymers comprising low surface tension (meth) acrylates PPG INDUSTRIES OHIO, INC. 2003-05-22 US disclosed
WO-2003027159-A2 COMPOSITIONS CONTAINING A LOW SURFACE TENSION (METH)ACRYLATE CONTAINING BLOCK COPOLYMER PPG INDUSTRIES OHIO, INC. (US) 2003-04-03 WO disclosed
WO-2003027155-A1 COPOLYMERS COMPRISING LOW SURFACE TENSION (METH)ACRYLATES PPG INDUSTRIES OHIO, INC. (US) 2003-04-03 WO disclosed
EP-0271212-B1 PROCESS FOR PREPARATION OF CARBOXYLIC ACID ESTER CONTAINING FLUORINE Tosoh Corporation (JP) 1992-09-16 EP disclosed
EP-0271212-A2 Process for preparation of carboxylic acid ester containing fluorine Tosoh Corporation (JP) 1988-06-15 EP disclosed
JP-S62241906-A FLUORINE-CONTAINING POLYMER TOSOH CORP 1987-10-22 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122218-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B ALDH1A1 3972/4885KMT2A 4654/4885TDP1 4655/4885
US-12324802-B2 Modulators of cystic fibrosis transmembrane conductance regulator CFTR, SCNN1G, SCNN1B ALDH1A1 3972/4885KMT2A 4654/4885TDP1 4655/4885
US-20230099745-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B ALDH1A1 3972/4885KMT2A 4654/4885TDP1 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.